



NDA 21-572/S-043
NDA 21-572/S-044

SUPPLEMENT APPROVAL

Cubist Pharmaceuticals, Inc.
Attention: Jennifer Liscouski
Senior Manager, Regulatory Affairs
65 Hayden Avenue
Lexington, MA 02421

Dear Ms. Liscouski:

Please refer to your Supplemental New Drug Applications (sNDAs) dated April 8, 2013, received April 8, 2013, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for CUBICIN (daptomycin for injection) 500 mg/vial.

We acknowledge receipt of your amendment (S-043) dated September 23, 2013.

These “Changes Being Effected” supplemental new drug applications provide for the following:

- S-043: Updates to Section 6.2, **Post-Marketing Experience** subsection of the package insert to include the additional adverse reactions “angioedema” and “drug rash with eosinophilia and systemic symptoms” (DRESS) under *Immune System Disorders*.
- S-044: An updated telephone number in the **HIGHLIGHTS, ADVERSE REACTIONS** section to allow for the reporting of suspected adverse reactions.

APPROVAL & LABELING

We have completed our review of these supplemental applications, as amended, and they are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at:
<http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>.

Content of labeling must be identical to the enclosed labeling (text for the package insert), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at:

<http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call J. Christopher Davi, MS, Senior, Regulatory Project Manager, at (301) 796-0702.

Sincerely,

{See appended electronic signature page}

Katherine A. Laessig, MD
Deputy Director
Division of Anti-Infective Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

ENCLOSURE: Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

KATHERINE A LAESSIG
11/22/2013